Ginkgo Bioworks Holdings (DNA)vsNovartis AG ADR (NVS)
DNA
Ginkgo Bioworks Holdings
$8.22
-9.17%
HEALTHCARE · Cap: $577.47M
NVS
Novartis AG ADR
$148.38
-2.52%
HEALTHCARE · Cap: $289.19B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 37270% more annual revenue ($56.58B vs $151.40M). NVS leads profitability with a 23.9% profit margin vs -201.0%. NVS earns a higher WallStSmart Score of 49/100 (D+).
DNA
Avoid29
out of 100
Grade: F
NVS
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-7.5%
Fair Value
$8.70
Current Price
$8.22
$0.48 premium
Margin of Safety
-65.2%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -68.7% — below average capital efficiency
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : DNA
The strongest argument for DNA centers on Price/Book.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : DNA
The primary concerns for DNA are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Key Dynamics to Monitor
DNA profiles as a turnaround stock while NVS is a declining play — different risk/reward profiles.
DNA carries more volatility with a beta of 1.80 — expect wider price swings.
NVS is growing revenue faster at -0.7% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (49/100 vs 29/100), backed by strong 23.9% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ginkgo Bioworks Holdings
HEALTHCARE · BIOTECHNOLOGY · USA
Ginkgo Bioworks Holdings (DNA) is a leader in synthetic biology, specializing in advanced genetic engineering to develop tailor-made bioengineered organisms for diverse applications, including pharmaceuticals, agriculture, and industrial biotech. Its cutting-edge platform enhances cellular design for efficient manufacturing processes, positioning the company to meet pressing global challenges such as climate change and food security. Ginkgo's unique capabilities and focus on sustainable biotechnology solutions not only address growing market demands for bio-based alternatives but also signify a compelling growth trajectory, underscoring its potential to drive transformative impact across multiple industries.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?